Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 237 participants.
Also called NCT02827903
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 237 participants
- Registry
-
NCT02827903
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02827903. Randomized; double masking; primary purpose treatment. Start 2016-01-15 (actual); primary completion 2017-11-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia
- Condition
- Type 2 Diabetes
- Condition
- Dyslipidemia
- Intervention (Drug)
- Metformin + Rosuvastatin
- Intervention (Drug)
- Metformin + placebo
- Intervention (Drug)
- placebo + Rosuvastatin
- Lead sponsor
- Jeil Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct02827903- Content hash
d64cc4ee2a28a6ad95933c6d5a95b4296eb84ab7f6be762d270da496ed15ca1b